Article
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
Future oncology (London, England) - 1 Jun 2018
Passiglia Francesco, Commendatore Oriana, Vitali Milena, Conca Raffaele
Abstract excerpt
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.